Agios Pharmaceuticals AGIO Change in Lease Liabilities
Change in Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's change in lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's change in lease liabilities?
- Agios Pharmaceuticals (AGIO) reported change in lease liabilities of -$4.46M in Q1 2026.
- How has Agios Pharmaceuticals's change in lease liabilities changed year-over-year?
- Agios Pharmaceuticals's change in lease liabilities decreased by 10.2% year-over-year, from -$4.05M to -$4.46M.
- What is the long-term trend for Agios Pharmaceuticals's change in lease liabilities?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's change in lease liabilities has grown at a 22.2% compound annual growth rate (CAGR), from -$7.53M to -$16.78M.
- What does change in lease liabilities mean?
- Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.